Darinaparsin

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Darinaparsin is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2022. Recorded indications include Refractory peripheral T-cell lymphoma.

• Indications: Refractory peripheral T-cell lymphoma.
• ATC code: L01XX82 (Other antineoplastic agents).
• Molecular formula: C12H22AsN3O6S; molecular weight 411.30 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Refractory peripheral T-cell lymphoma

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2022-06-20	PMDA	—	SOLASIA PHARMA K.K

ATC classification

ATC code	Therapeutic hierarchy
L01XX82	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Darinaparsin is on its molecule page.

• Molecular formula: C₁₂H₂₂AsN₃O₆S
• Molecular weight: 411.30 g/mol
• CAS number: 69819-86-9
• InChIKey: JGDXFQORBMPJGR-YUMQZZPRSA-N
• PubChem CID: 11683005

C[As](C)SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Darinaparsin used for?

DrugCentral lists the following indications for Darinaparsin: Refractory peripheral T-cell lymphoma.

When was Darinaparsin first approved?

Darinaparsin was first approved by the PMDA in 2022.

What is the chemical formula of Darinaparsin?

Darinaparsin has the molecular formula C12H22AsN3O6S and a molecular weight of 411.30 g/mol.

Sources

• DrugCentral drug card 5685 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3247378 — compound record and bioactivity
• PubChem CID 11683005 — chemical identifiers
• DrugBank DB06179 — drug record
• FDA UNII 9XX54M675G — substance identity

How this page is built: methodology · editorial policy & corrections.